Fundz

MAIA Biotechnology secures a $2.3 million grant from the National Institutes of Health for its THIO-101 Phase 2 trial aimed at treating advanced non-small cell lung cancer.

PUBLIC · MAIASep 24, 2025

Amount Raised

$2.3 Million

Round Type

Grant

ChicagoBiotechnologyHealth CareScience And EngineeringMedicalTherapeutics

Investors

National Institutes Of Health

Description

MAIA Biotechnology has been awarded a $2.3 million grant by the NIH for the THIO-101 Phase 2 clinical trial. This funding will mainly support patient enrollment costs in the U.S. for adults resistant to previous treatment. The grant funds will be allocated over three years from 2025 to 2027

Who else raised in Science And Engineering and Medical around the same time

Companies in the same sectors as MAIA Biotechnology that raised within 45 days of this round, from Fundz verified event records.

  • Faeth Therapeutics raised $25M (Funding Round) on October 20, 2025.
  • Theriva Biologics raised $13M on October 17, 2025.
  • Theriva Biologics raised $4M (Funding Round) on October 16, 2025.
  • Aerska raised $21M (Seed) on October 1, 2025.
  • Mati Therapeutics raised $9.9M on September 30, 2025.
  • Nuclide Therapeutics raised $6.7M (Seed) on September 22, 2025.

Who to call at MAIA Biotechnology, and when

A new round usually means MAIA Biotechnology is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day MAIA Biotechnology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at MAIA Biotechnology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at MAIA Biotechnology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

MAIA Biotechnology

Location

Chicago, Illinois, United States

About

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment MAIA Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsSean S., Senior Director, Human ResourcesSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for MAIA Biotechnology's next move

See what Strategic adds

MAIA Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.